Empagliflozin may protect the heart by altering the expression of genes including Apoe, Apoc1, Saa2, Apoa2, and Pon1, which are all involved in lipid metabolism disturbance in obesity. The gene discussed is APOA2; the disease is obesity due to melanocortin 4 receptor deficiency.